Inhibitory effect of microRNA-21 on pathways and mechanisms involved in cardiac fibrosis development.
Amirreza KhalajiSaba MehrtabarArmin JabraeilipourNadia DoustarHamed Rahmani YoushanloueiAmir TahavvoriPayam FattahiSeyed Mohammad Amin AlaviSeyed Reza TahaAndarz Fazlollahpour-NaghibiMahdieh Shariat ZadehPublished in: Therapeutic advances in cardiovascular disease (2024)
Cardiac fibrosis is a pivotal cardiovascular disease (CVD) process and represents a notable health concern worldwide. While the complex mechanisms underlying CVD have been widely investigated, recent research has highlighted microRNA-21's (miR-21) role in cardiac fibrosis pathogenesis. In this narrative review, we explore the molecular interactions, focusing on the role of miR-21 in contributing to cardiac fibrosis. Various signaling pathways, such as the RAAS, TGF-β, IL-6, IL-1, ERK, PI3K-Akt, and PTEN pathways, besides dysregulation in fibroblast activity, matrix metalloproteinases (MMPs), and tissue inhibitors of MMPs cause cardiac fibrosis. Besides, miR-21 in growth factor secretion, apoptosis, and endothelial-to-mesenchymal transition play crucial roles. miR-21 capacity regulatory function presents promising insights for cardiac fibrosis. Moreover, this review discusses numerous approaches to control miR-21 expression, including antisense oligonucleotides, anti-miR-21 compounds, and Notch signaling modulation, all novel methods of cardiac fibrosis inhibition. In summary, this narrative review aims to assess the molecular mechanisms of cardiac fibrosis and its essential miR-21 function.
Keyphrases
- cell proliferation
- long non coding rna
- pi k akt
- left ventricular
- long noncoding rna
- signaling pathway
- cardiovascular disease
- growth factor
- poor prognosis
- healthcare
- oxidative stress
- heart failure
- bone marrow
- risk assessment
- endoplasmic reticulum stress
- human health
- epithelial mesenchymal transition
- climate change
- high speed
- atrial fibrillation
- health information